XML 78 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 1,804 $ 1,975
Accounts receivables, net of allowance for credit losses of $127 million and $135 million as of March 31, 2020 and December 31, 2019 5,189 5,676
Inventories 4,290 4,422
Prepaid expenses 977 870
Other current assets 538 434
Assets held for sale 86 87
Total current assets 12,884 13,464
Deferred income taxes 440 386
Other non-current assets 550 591
Property, plant and equipment, net 6,221 6,436
Operating lease right-of-use assets 489 514
Identifiable intangible assets, net 10,256 11,232
Goodwill 24,490 24,846
Total assets 55,330 57,470
Current liabilities:    
Short-term debt 1,630 2,345
Sales reserves and allowances 5,662 6,159
Accounts payables 1,710 1,718
Employee-related obligations 540 693
Accrued expenses 1,718 1,869
Other current liabilities 1,061 889
Total current liabilities 12,322 13,674
Long-term liabilities:    
Deferred income taxes 912 1,096
Other taxes and long-term liabilities 2,624 2,640
Senior notes and loans 24,473 [1] 24,562
Operating lease liabilities 411 435
Total long-term liabilities 28,420 28,733
Commitments and contingencies, see note 10
Total liabilities 40,742 42,407
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; March 31, 2020 and December 31, 2019: authorized 2,495 million shares; issued 1,201 million shares and 1,198 million shares, respectively 56 56
Additional paid-in capital 27,342 27,312
Accumulated deficit (6,887) (6,956)
Accumulated other comprehensive loss (2,852) (2,312)
Treasury shares as of March 31, 2020 and December 31, 2019 — 106 million ordinary shares (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 13,531 13,972
Non-controlling interests 1,057 1,091
Total equity 14,588 15,063
Total liabilities and equity $ 55,330 $ 57,470
[1] During the first quarter of 2020, Teva repaid at maturity $700 million of its 2.25% senior notes.